Amber L. Southwell

University of Central Florida — United States

Neuroscience · Life Sciences

35h-index4.5kcitations77works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Genetic Neurodegenerative Diseases(60), Mitochondrial Function and Pathology(33), Muscle Physiology and Disorders(20), Neurological disorders and treatments(12), RNA Research and Splicing(9)

Publications77 total

Neuron-derived extracellular vesicles in plasma present a potential non-invasive biomarker for Huntingtin protein and RNA assessment in Huntington disease
2025· 1 citedOpen Access
Challenges and advances for huntingtin detection in cerebrospinal fluid: in support of relative quantification
Biomarker Research·2025· 1 citedOpen Access
A tool to automate assessment of regional brain atrophy in mouse models of neurodegenerative disease
2024Open Access
Challenges and advances for huntingtin detection in cerebrospinal fluid: in support of relative quantification
2024· 1 citedOpen Access
I014 Development of an immunological antibody approach for the treatment of Huntington’s disease
2024Open Access
Corrigendum to “Reducing huntingtin by immunotherapy delays disease progression in a mouse model of Huntington disease” [Neurobiology of Disease, 2024 Jan:190:106376]
Neurobiology of Disease·2024Open Access
Reducing huntingtin by immunotherapy delays disease progression in a mouse model of Huntington disease
Neurobiology of Disease·2023· 4 citedOpen Access
D04 Challenges and advances in cerebrospinal fluid HTT detection: in support of relative quantification
2022
Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic
BioDrugs·2022· 105 citedOpen Access
Cerebrospinal fluid mutant huntingtin is a biomarker for huntingtin lowering in the striatum of Huntington disease mice
Neurobiology of Disease·2022· 22 citedOpen Access
Small molecule splicing modifiers with systemic HTT-lowering activity
Nature Communications·2021· 83 citedOpen Access
I01 Orally bioavailable small molecule splicing modifiers with systemic and even htt-lowering activity in vitro and in vivo
2021
I09 In vivo mtHTT protein reduction in the CNS and periphery by passive immunization with the monoclonal antibody C6–17
2021· 1 cited
Decision letter: A novel and accurate full-length HTT mouse model for Huntington’s disease
2021Open Access
Super-resolution imaging reveals extrastriatal synaptic dysfunction in presymptomatic Huntington disease mice
Neurobiology of Disease·2021· 27 citedOpen Access
Mutant Huntingtin Is Cleared from the Brain via Active Mechanisms in Huntington Disease
Journal of Neuroscience·2020· 65 citedOpen Access
The Interaction of Aging and Cellular Stress Contributes to Pathogenesis in Mouse and Human Huntington Disease Neurons
Frontiers in Aging Neuroscience·2020· 28 citedOpen Access
Decision letter: Histone deacetylase knockouts modify transcription, CAG instability and nuclear pathology in Huntington disease mice
2020Open Access
Biological Aging and the Cellular Pathogenesis of Huntington’s Disease
Journal of Huntington s Disease·2020· 48 citedOpen Access
Inhibiting cellular uptake of mutant huntingtin using a monoclonal antibody: Implications for the treatment of Huntington's disease
Neurobiology of Disease·2020· 17 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Michael R. Hayden(37), Yuanyun Xie(15), Niels H. Skotte(12), Crystal N. Doty(11), Erika B. Villanueva(9), Nicholas S. Caron(9), Sonia Franciosi(8), Paul H. Patterson(7), Michael E. Østergaard(7), Punit P. Seth(6), Matthew P. Parsons(6), Jeffrey B. Carroll(5), C. Frank Bennett(5), Holly Kordasiewicz(5), Kuljeet Vaid(5), Eric E. Swayze(5), Mahmoud A. Pouladi(5), Lisa M. Anderson(5), Sabine Waltl(5), Louisa Dal Cengio(5)